DNA倍体技术在宫颈癌和癌前病变筛查中的价值探讨

The Value of DNA Ploidy Technology in Cervical Cancer and Precancerous

目的：探讨DNA倍体技术在宫颈癌和癌前病变筛查中的价值。方法：选取1538例待筛查者，先进行DNA倍体分析之后进行病理活检检查，比较DNA倍体分析结果与病理活检检查的差异。结果：本组共取材1538例样本，DNA倍体分析阴性者1425例，阴性率92.7%，51岁及以上阳性率最高，其次为31~40岁者，病理检查确诊宫颈癌或者癌前病变者55例，DNA倍体分析存在2例漏诊，其诊断率达到96.4%。结论：DNA倍体分析对于宫颈癌及其癌前病变的早期诊断及筛查，诊断符合率高，取材方便，检查简单无创，是一种较为可靠的普查方法。

Objective：To investigate the value of DNA ploidy technology in cervical cancer and precancerous. Method：1538 cases were be screened,the first pathological biopsy performed after DNA ploidy analysis,then differences between the DNA ploidy and biopsy examination were compared.Result：The samples were drawn from 1538 cases,DNA ploidy negative analysis was 1425 cases,negative rate was 92.7%,the highest positive rate was over 51 years old and followed by 31 to 40 years old,pathological diagnosis of cervical cancer or precancerous lesions was 55 cases,DNA ploidy analysis missed the presence of two cases,the diagnosis rate was 96.4%.Conclusion：DNA ploidy analysis and screening for early diagnosis of cervical cancer and precancerous lesions,the diagnostic accuracy rate is high,it can easily obtain and check the simple non-invasive,so it is a more reliable screening method.